Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours

被引：0
|
作者：
Lu, S. [1 ]
De Braud, F. G. M. [2 ]
Fan, Y. [3 ]
Hu, X. [4 ]
Ohe, Y. [5 ]
Yu, Y. [6 ]
Ahn, M-J. [7 ]
Cassier, P. [8 ]
Lin, J. J. [9 ]
Paz-Ares, L. [10 ]
Xue, C. [11 ]
Bordogna, W. [12 ]
Patel, S. [13 ]
Zeuner, H. [12 ]
Dong, X. [14 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Med Oncol, Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Univ Milan, Med Oncol & Haematol Dept, Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Zhejiang Canc Hosp, Dept Med Thorac Oncol, Hangzhou, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[5] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[6] Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[7] Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea
[8] Ctr Leon Berard, Dept Med, Lyon, France
[9] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA USA
[10] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[11] F Hoffmann La Roche Ltd, Biostat, Mississauga, ON, Canada
[12] F Hoffmann La Roche Ltd, Prod Dev Med Affairs, Basel, Switzerland
[13] Genentech Inc, Prod Dev Oncol, South San Francisco, CA USA
[14] Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1852
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
666P
引用
收藏
页码：S468 / S469
页数：2
相关论文
共 50 条
  • [21] Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
    Conley, A. P.
    Demetri, G. D.
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    Cassier, P.
    Siena, S.
    Ahn, M-J.
    Buchschacher, G. L., Jr.
    Seto, T.
    Chee, C. E.
    Krzakowski, M.
    Ou, S-H. I.
    Grohe, C.
    Zagonel, V.
    Spira, A.
    Cheng, A.
    Kapre, A.
    Piault, E.
    Rolfo, C. D.
    ANNALS OF ONCOLOGY, 2020, 31 : S471 - S472
  • [22] Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
    Fan, Y.
    Drilon, A.
    Chiu, C. -H.
    Bowles, D. W.
    Loong, H. H. F.
    Siena, S.
    Goto, K.
    Krzakowski, M.
    Ahn, M. -J.
    Murakami, H.
    Dziadziuszko, R.
    Zeuner, H.
    Pitcher, B.
    Cheick, D.
    Krebs, M. G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S89 - S90
  • [23] Updated Efficacy and Safety of Entrectinib in Patients (PTS) with NTRK Fusion-Positive (NTRK plus ) Tumors: Integrated Analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
    Folprecht, Gunnar
    Rolfo, Christian
    Dziadziuszko, Rafal
    Doebele, Robert
    Demetri, George
    Simmons, Brian
    Huang, Xinhui
    Pitcher, Bethany
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 216 - 217
  • [24] Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Rolfo, C.
    Dziadziuszko, R.
    Doebele, R. C.
    Demetri, G.
    Simmons, B.
    Aziez, A.
    Huang, X.
    Osborne, S.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
    Dziadziuszko, Rafal
    Krebs, Matthew G.
    De Braud, Filippo
    Siena, Salvatore
    Drilon, Alexander
    Doebele, Robert C.
    Patel, Manish R.
    Cho, Byoung Chul
    Liu, Stephen V.
    Ahn, Myung-Ju
    Chiu, Chao-Hua
    Farago, Anna F.
    Lin, Chia-Chi
    Karapetis, Christos S.
    Li, Yu-Chung
    Day, Bann-mo
    Chen, David
    Wilson, Timothy R.
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1253 - +
  • [26] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, A.
    LANCET ONCOLOGY, 2020, 22 (10): : E428 - E428
  • [27] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
  • [28] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
  • [29] Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
    Fan, Yun
    Drilon, Alexander
    Chiu, Chao-Hua
    Loong, Herbert H. F.
    Siena, Salvatore
    Krzakowski, Maciej
    Dziadziuszko, Rafal
    Zeuner, Harald
    Xue, Cloris
    Krebs, Matthew G.
    CLINICAL LUNG CANCER, 2024, 25 (02) : e81 - e86.e4
  • [30] Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Demetri, G. D.
    Paz-Ares, L.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Kim, E. S.
    Blakely, C.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Multani, P. S.
    Johnson, A. D.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2018, 29
12345